| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We reported that retrotransposon activated a glomerular crescent forming phase in mouse BSA nephritis and a reverse transcriptase inhibitor, Efavirenz, clearly prevented crescent formation. We tried the same protocol to the hL1-EGFP Tg mice which over-express human retrotransposon and show the retrotransposition site by EGFP. By Immunofluorescence, EGFP was not detected in the BSA nephritis tissues. It was suggested that abundant small DNA driven by L1 retrotransposon is a possible inducer of crescent formation.
|
